To read the full story, subscribe or sign in.

China's Bio-Thera launches phase III trial of HER2-positive breast cancer ADC candidate

Nov. 14, 2018

HONG KONG – Chinese biologics and biosimilars maker Bio-Thera Solutions Ltd. kicked off a phase III trial of its HER2 antibody-drug conjugate (ADC), BAT-8001, targeting HER2-positive metastatic cancer.

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for March 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 28, 2025

FDA says changes in Dexcom G6, G7 sensors constitute misbranding

BioWorld MedTech

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures...

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...